News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Uroplasty, Inc. (UPI) to Participate in Two Upcoming Investor Conferences


11/7/2012 2:29:31 PM

MINNEAPOLIS, Nov. 6, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in two upcoming investor conferences in November the Stephens Fall Investment Conference and the Lazard 9th Annual Healthcare Conference. Detailed information is provided below:

What:

Stephens Fall Investment Conference

Where:

New York Palace Hotel, New York, NY

Date:

Tuesday, November 13, 2012

Time:

4:00 pm ET



What:

Lazard 9th Annual Healthcare Conference

Where:

Pierre Hotel, New York, NY

Date:

Wednesday, November 14, 2012

Time:

11:00 am ET



David Kaysen, President and CEO, and Medi Jiwani, Chief Financial Officer, will discuss recent financial results and current corporate developments at both conferences.

Uroplasty will offer a live audio webcast of both events on the Company's website, www.uroplasty.com, under Investor Information. An archived replay of the presentation will be available for 30 days, also at www.uroplasty.com.

About Uroplasty, Inc.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:


Uroplasty, Inc.

EVC Group

David Kaysen, President and CEO, or

Doug Sherk/Jenifer Kirtland (Investors),

Medi Jiwani, Vice President, CFO, Treasurer

415.568.9349

952.426.6140

Chris Gale (Media), 646.201.5431

SOURCE Uroplasty, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES